The Invesco Perpetual European Equity Income Fund aims to generate a rising level of income, together with long-term capital growth investing primarily into European equities, excluding the UK.
Name | % Net Assets |
---|---|
Roche | 7.5% |
Koninklijke KPN | 4.6% |
Novartis | 4.4% |
Total | 3.6% |
Thales | 3.6% |
GDF Suez | 3.6% |
Oesterreich Post | 3.5% |
Vivendi Universal | 3.3% |
Reed Elsevier | 2.9% |
Banque Cantonale Vaudoise | 2.7% |
Key | % Net Assets |
---|---|
Roche | 7.5% |
Koninklijke KPN | 4.6% |
Novartis | 4.4% |
Total | 3.6% |
Other | 79.9% |
Date | 21-Nov-2024 |
---|---|
NAV | 134.19p |
Currency | GBP |
Change | -0.100p |
% | -0.07% |
YTD change | -12.78p |
YTD % | -8.70% |
Fund Inception | 12/12/2007 |
---|---|
Fund Manager | n/a |
TER | - |
Minimum Investment | |
---|---|
Initial | n/a |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | n/a |
Exit | n/a |
Name | % |
---|---|
No risk data available. |
You are here: research